Emmanuel Labourier

Emmanuel Labourier

Auto-generated profile, based on publicly available information

Emmanuel Labourier

Asuragen Inc., Austin, Texas

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2005 in Cell
Verified
Journal Article
Closed access
SJSteven M. Johnson
Steven M. Johnson
HGHelge Grosshans
Helge Grosshans
JSJaclyn Shingara
Jaclyn Shingara
MBMike Byrom
Mike Byrom
RJRich Jarvis
Rich Jarvis
FSFrank J. Slack
Frank J. Slack

27 February 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JCJordan M. Cummins
Jordan M. Cummins
YHYiping He
Yiping He
RLRebecca J. Leary
Rebecca J. Leary
RPRay Pagliarini
Ray Pagliarini
LDLuis A. Diaz
Luis A. Diaz
VVVictor E. Velculescu
Victor E. Velculescu
MicroRNAs (miRNAs) are a class of small noncoding RNAs that have important regulatory roles in multicellular organisms. The public miRNA database contains 321 human miRNA sequences, 234 of which have been experimentally verified. To explore the possibility that additional miRNAs are present in the human genome, we have developed an experimental approach called miRNA serial analysis of gene expression (miRAGE) and used it to perform the largest experimental analysis of human miRNAs to date. Sequence analysis of 273,966 small RNA tags from human colorectal cells allowed us to identify 200 known mature miRNAs, 133 novel miRNA candidates, and 112 previously uncharacterized miRNA* forms. To aid in the evaluation of candidate miRNAs, we disrupted the Dicer locus in three human colorectal cancer cell lines and examined known and novel miRNAs in these cells. These studies suggest that the human genome contains many more miRNAs than currently identified and provide an approach for the large-scale experimental cloning of novel human miRNAs in human tissues.

22 January 2007 in Oncogene
Verified
Journal Article
Closed access
ASA E Szafranska
A E Szafranska
TDT S Davison
T S Davison
JJJ John
J John
TCT Cannon
T Cannon
BSB Sipos
B Sipos
SHStephan Hahn
Stephan Hahn

1 May 1996 in Nature
Verified
Journal Article
Closed access
FRFerdinand Rossi
Ferdinand Rossi
ELEmmanuel Labourier
Emmanuel Labourier
TFThierry Forné
Thierry Forné
GDGilles Divita
Gilles Divita
JDJean Derancourt
Jean Derancourt
GCGuy Cathala
Guy Cathala

1 July 2015 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
ELEmmanuel Labourier
Emmanuel Labourier
ASAlexander Shifrin
Alexander Shifrin
ABAnne E. Busseniers
Anne E. Busseniers
MLMark A. Lupo
Mark A. Lupo
MMMonique L. Manganelli
Monique L. Manganelli
SBSylvie Beaudenon-Huibregtse
Sylvie Beaudenon-Huibregtse
Context: Molecular testing for oncogenic mutations or gene expression in fine-needle aspirations (FNAs) from thyroid nodules with indeterminate cytology identifies a subset of benign or malignant lesions with high predictive value. Objective: This study aimed to evaluate a novel diagnostic algorithm combining mutation detection and miRNA expression to improve the diagnostic yield of molecular cytology. Setting: Surgical specimens and preoperative FNAs (n = 638) were tested for 17 validated gene alterations using the miRInform Thyroid test and with a 10-miRNA gene expression classifier generating positive (malignant) or negative (benign) results. Design: Cross-sectional sampling of thyroid nodules with atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) or follicular neoplasm/suspicious for a follicular neoplasm (FN/SFN) cytology (n = 109) was conducted at 12 endocrinology centers across the United States. Qualitative molecular results were compared with surgical histopathology to determine diagnostic performance and model clinical effect. Results: Mutations were detected in 69% of nodules with malignant outcome. Among mutation-negative specimens, miRNA testing correctly identified 64% of malignant cases and 98% of benign cases. The diagnostic sensitivity and specificity of the combined algorithm was 89% (95% confidence interval [CI], 73–97%) and 85% (95% CI, 75–92%), respectively. At 32% cancer prevalence, 61% of the molecular results were benign with a negative predictive value of 94% (95% CI, 85–98%). Independently of variations in cancer prevalence, the test increased the yield of true benign results by 65% relative to mRNA-based gene expression classification and decreased the rate of avoidable diagnostic surgeries by 69%. Conclusions: Multiplatform testing for DNA, mRNA, and miRNA can accurately classify benign and malignant thyroid nodules, increase the diagnostic yield of molecular cytology, and further improve the preoperative risk-based management of benign nodules with AUS/FLUS or FN/SFN cytology.

25 July 2005 in RNA
Verified
Journal Article
Closed access
PDF file
JSJaclyn Shingara
Jaclyn Shingara
KKKerri Keiger
Kerri Keiger
JSJeffrey Shelton
Jeffrey Shelton
WLWalairat Laosinchai-Wolf
Walairat Laosinchai-Wolf
PPPatricia Powers
Patricia Powers
ELEmmanuel Labourier
Emmanuel Labourier
A monthly journal publishing high-quality, peer-reviewed research on all topics related to RNA and its metabolism in all organisms